EGFR and adenocarcinoma: Jin et al. performed the first genomic profiling of EGFR-mutant SCC and reported a higher mutation frequency of neurofibromatosis (Neurofibromatosis type 1-NF1), ataxia telangiectasia and Rad3 (ATR) related gene, and breast cancer (BReast CAncer gene 1-BRCA1) compared with EGFR-mutant adenocarcinomas [170].